Equillium to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at Fontainebleau Miami Beach Hotel, and at the Jefferies Healthcare Conference on June 8, 2022, at Marriott Marquis, New York City. The company aims to provide updates on its clinical programs and will hold one-on-one meetings. Both presentations will be accessible via webcast, with archived replays available for 90 days. Equillium is focused on developing therapeutics for severe autoimmune disorders.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference.

Management will provide a high-level overview of the company, clinical assets and ongoing clinical programs, and will be available for one-on-one meetings during both conferences.

Conference:		H.C. Wainwright Global Investment Conference
Location:		Fontainebleau Miami Beach Hotel
Date:		Tuesday, May 24, 2022
Time:		6:30 AM Pacific Time | 9:30 AM Eastern Time
Conference:		Jefferies Healthcare Conference
Location:		Marriott Marquis, New York City
Date:		Wednesday, June 8, 2022
Time:		8:00 AM Pacific Time | 11:00 AM Eastern Time

Webcast access for both presentations will be available on the Events & Presentations section of the Company’s website. An archived replay of both conferences will be available for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel immunomodulatory assets targeting immuno-inflammatory pathways. Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, is currently in a Phase 3 study for patients with acute graft-versus-host disease (aGVHD) and is in a Phase 1b study for patients with lupus/lupus nephritis. EQ101, a first-in-class tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling patients in an alopecia areata study in the second half of 2022. EQ102, a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Phase 1 study anticipated to include normal healthy volunteers and celiac disease patients in the second half of 2022.

For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with aGVHD or lupus/lupus nephritis with itolizumab, Equillium’s plans and expected timing for developing itolizumab including the expected timing of initiating, completing and announcing further results from the EQUATE and EQUALISE studies, Equillium’s plans and expected timing for developing EQ101 and EQ102 including the expected timing of initiating, completing and announcing further results from Phase 2 and Phase 1 studies, respectively, the potential benefits and impact of the Bioniz acquisition, the potential for any of Equillium’s ongoing or planned clinical studies to show safety or efficacy, statements regarding the impact of new members of the board of directors, Equillium’s anticipated timing of regulatory review and feedback, Equillium’s cash runway, and Equillium’s plans and expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to the abilities of the leadership team to perform as expected; Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical studies and the reporting of data therefrom; whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; uncertainties related to Equillium’s capital requirements; and having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting EDGAR on the SEC web site at http://www.sec.gov and on the Company’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005501/en/

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com



Media Contacts

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

Source: Equillium, Inc.

FAQ

When is Equillium presenting at the H.C. Wainwright Global Investment Conference?

Equillium will present at the H.C. Wainwright Global Investment Conference on May 24, 2022.

Where is the Jefferies Healthcare Conference taking place?

The Jefferies Healthcare Conference is being held at the Marriott Marquis in New York City.

What is the date of the Jefferies Healthcare Conference presentation by Equillium?

Equillium's presentation at the Jefferies Healthcare Conference is scheduled for June 8, 2022.

What time will Equillium's presentations at the conferences occur?

The presentation at H.C. Wainwright is at 6:30 AM Pacific Time, and at Jefferies Healthcare Conference, it is at 8:00 AM Pacific Time.

Will Equillium's conference presentations be available for viewing later?

Yes, both presentations will be available via webcast, with archived replays accessible for 90 days.